$60 and Soon: The Reasons Why...The following is a list of reasons why I think RVX will be sold sooner than later and for $60 or more. If any of these warrant further discussion, which I'm sure they do, then bring the questions forward. They're offered in no particular order and are not guaranteed to be all-inclusive. I have researched so much and written so much that putting it all in a short list form is impossible. This list is not quite the same as the one I posted last month.
Here they are:
(A) Largest drug market potential of all time.
(B) Trial-proven benefits of Apo-A1/HDL levels and therapies.
(C) Cardiologists agree Apo-A1/HDL therapy is the most likely path for sucess.
(D) Small molecule - broad application.
(E) Potential for chronic & acute care.
(F) Probable exclusivity in its area for RVX as a result of assaying technology.
(G) The failure of other therapies.
(H) The urgency that exists due to pharmas' expiring statin patents.
(I) Minimum buyout price already declared by Pfizer at $1.3 billion US.
(J) Too far away from Phase II or III trials to make any difference in sale price.
(K) Potential for at least a dozen other indications including Alzheimer's.
(L) The premier cardiologists in the world are associated in some way with RVX.
(M) Early sale suggested by acute care and assaying technology.
(N) Virtually unlimited number of drug vs indication combinations.
(O) Small payback if a pharma develops an patentable Apo-A1 drug.
(P) Speedy trials due to probable FDA acceptance of new imaging technologies.